Le Lézard
Classified in: Health
Subject: ACC

DSM - Repurchase of Shares (17 - 21 June 2019)


HEERLEN, Netherlands, June 25, 2019 /PRNewswire/ --

Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, has repurchased 94,194 of its own shares in the period from 17 June 2019 up to and including 21 June 2019 at an average price of ?108.56. This is in accordance with the repurchase announced on 14 March 2019, covering the intended reduction of issued capital as well as commitments under share-based compensation plans and for stock dividends. The consideration of this repurchase was ?10.2 million.

     (Logo: https://mma.prnewswire.com/media/657851/DSM_Logo.jpg )

The total number of shares repurchased under this program to date is 2,447,549 shares for a total consideration of ?249.2 million.

For more detailed information see 'Daily transaction details Share Repurchase Program announced 14 March 2019'.

DSM - Bright Science. Brighter Living.tm 

Royal DSM is a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living. DSM's purpose is to create brighter lives for all. DSM addresses with its products and solutions some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders - customers, employees, shareholders, and society at large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about ?10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com.

Or find us on:

Facebook
Twitter
LinkedIn
YouTube

 

    PRN NLD


These press releases may also interest you

at 10:54
Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of OBGEMSAtm (vibegron under the international...

at 10:49
Sustain Exchange LLC is proud to announce a partnership with HearMe, a leading behavioral health peer support platform focused on ensuring healthy lives and promoting well-being. As part of this innovative partnership, SustainAble Exchange will...

at 10:45
C?N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, today announced a partnership agreement with Mediford Corporation, a PHC Holdings Corporation (TSE 6523) Group Company and premier...

at 10:35
BeiGene, Ltd. , a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company's strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets. This...

at 10:30
Invensify, Inc., Santa Clara, California, has introduced a power efficient, temperature-controlled shipping container designed to maintain stable storage temperatures for high-value pharmaceuticals before and during transport to last-mile cold chain...

at 10:30
Oligonucleotide Synthesis Market in terms of revenue was estimated to be worth $8.8 billion in 2024 and is poised to reach $19.7 billion by 2029, growing at a CAGR of 17.5% from 2024 to 2029 according to a new report by MarketsandMarketstm. One of...



News published on and distributed by: